SCHEMBL17545288

SCHEMBL17545288

CC(=O)N1CCc2cc(Cl)c(S(=O)(=O)Nc3ncccn3)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
PKM P14618 1/20 0.50
KMT2A Q03164 1/20 0.50
CYP11B2 P19099 2/20 0.47
TRIM24 O15164 6/20 0.46
ACLY P53396 1/20 0.46
SYK P43405 1/20 0.45
NOTUM Q6P988 2/20 0.44
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19219765 0.90 LMNA (0.40) LMNAPKMKMT2ACYP11B2TRIM24
SCHEMBL17545074 0.87 KMT2A (0.52) LMNAPKMKMT2ACYP11B2TRIM24
SCHEMBL17545337 0.87 ACLY (0.60) LMNAPKMKMT2ATRIM24ACLY
SCHEMBL17545149 0.83 USP2 (0.53) LMNAPKMKMT2ACYP11B2TRIM24
SCHEMBL17545073 0.83 CYP11B2 (0.52) LMNAPKMKMT2ACYP11B2TRIM24
SCHEMBL15882573 0.82 NOTUM (0.51) LMNAPKMKMT2ACYP11B2TRIM24
SCHEMBL29707960 0.82 NOTUM (0.51) LMNAPKMKMT2ACYP11B2TRIM24
SCHEMBL18391782 0.82 LMNA (0.47) LMNAPKMKMT2ACYP11B2TRIM24
SCHEMBL21469287 0.81 ALDH1A1 (0.39) LMNAKMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL17545211 0.80 TRIM24 (0.47) LMNAPKMKMT2ACYP11B2TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021469-B2 Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same LOYOLA UNIVERSITY OF CHICAGO (US) 2021-06-01 US disclosed
US-20190337931-A1 INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME LOYOLA UNIVERSITY OF CHICAGO 2019-11-07 US disclosed
EP-3180312-B1 INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME UNIV LOYOLA CHICAGO (US) 2019-10-16 EP disclosed
US-10385040-B2 Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same LOYOLA UNIVERSITY OF CHICAGO (US) 2019-08-20 US disclosed
US-20170226090-A1 INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-08-10 US disclosed
WO-2016025637-A1 INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME LOYOLA UNIVERSITY OF CHICAGO (US) 2016-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385040-B2 Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same INMT, MGAM, NNMT LMNA 3262/4885PKM 2308/4885KMT2A 1720/4885
US-20190337931-A1 INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME INMT, MGAM, NNMT LMNA 3262/4885PKM 2308/4885KMT2A 1720/4885
US-11021469-B2 Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same INMT, MGAM, NNMT LMNA 3262/4885PKM 2308/4885KMT2A 1720/4885
US-20170226090-A1 INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME INMT, MGAM, NNMT LMNA 3262/4885PKM 2308/4885KMT2A 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.